These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG mBio; 2020 Sep; 11(5):. PubMed ID: 32913009 [TBL] [Abstract][Full Text] [Related]
4. Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation. Beirag N; Kumar C; Madan T; Shamji MH; Bulla R; Mitchell D; Murugaiah V; Neto MM; Temperton N; Idicula-Thomas S; Varghese PM; Kishore U Front Immunol; 2022; 13():960733. PubMed ID: 35967323 [TBL] [Abstract][Full Text] [Related]
5. Properties of Coronavirus and SARS-CoV-2. Malik YA Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926 [TBL] [Abstract][Full Text] [Related]
6. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S Cells; 2021 Apr; 10(4):. PubMed ID: 33917481 [TBL] [Abstract][Full Text] [Related]
7. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction. Joseph J; Karthika T; Das VRA; Raj VS Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189 [TBL] [Abstract][Full Text] [Related]
9. Development of an in vitro model for animal species susceptibility to SARS-CoV-2 replication based on expression of ACE2 and TMPRSS2 in avian cells. Kapczynski DR; Sweeney R; Spackman E; Pantin-Jackwood M; Suarez DL Virology; 2022 Apr; 569():1-12. PubMed ID: 35217403 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2. Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671 [TBL] [Abstract][Full Text] [Related]
11. Creation of transgenic mice susceptible to coronaviruses: a platform for studying viral pathogenesis and testing vaccines. Battulin NR; Serov OL Vavilovskii Zhurnal Genet Selektsii; 2022 Jul; 26(4):402-408. PubMed ID: 35864938 [TBL] [Abstract][Full Text] [Related]
12. Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions. Hassanin AA; Haidar Abbas Raza S; Ahmed Ujjan J; Aysh ALrashidi A; Sitohy BM; Al-Surhanee AA; Saad AM; Mohamed Al-Hazani T; Osman Atallah O; Al Syaad KM; Ezzat Ahmed A; Swelum AA; El-Saadony MT; Sitohy MZ Saudi J Biol Sci; 2022 Apr; 29(4):1981-1997. PubMed ID: 34924802 [TBL] [Abstract][Full Text] [Related]
13. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection. Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS J Biol Chem; 2021; 296():100759. PubMed ID: 33965375 [TBL] [Abstract][Full Text] [Related]
14. A SARS-CoV-2-Related Virus from Malayan Pangolin Causes Lung Infection without Severe Disease in Human ACE2-Transgenic Mice. Liu MQ; Lin HF; Li J; Chen Y; Luo Y; Zhang W; Hu B; Tian FJ; Hu YJ; Liu YJ; Jiang RD; Gong QC; Li A; Guo ZS; Li B; Yang XL; Tong YG; Shi ZL J Virol; 2023 Feb; 97(2):e0171922. PubMed ID: 36688655 [TBL] [Abstract][Full Text] [Related]
15. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. Li K; Meyerholz DK; Bartlett JA; McCray PB mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553 [TBL] [Abstract][Full Text] [Related]
16. A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant. Sevenich M; van den Heuvel J; Gering I; Mohrlüder J; Willbold D J Virol; 2022 Jul; 96(13):e0068522. PubMed ID: 35674432 [TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells. Verma D; Church TM; Swaminathan S J Virol; 2021 Jun; 95(13):e0019221. PubMed ID: 33853968 [TBL] [Abstract][Full Text] [Related]
18. [Source of the COVID-19 pandemic: ecology and genetics of coronaviruses (Betacoronavirus: Coronaviridae) SARS-CoV, SARS-CoV-2 (subgenus Sarbecovirus), and MERS-CoV (subgenus Merbecovirus).]. Lvov DK; Alkhovsky SV Vopr Virusol; 2020; 65(2):62-70. PubMed ID: 32515561 [TBL] [Abstract][Full Text] [Related]
19. Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling. Frolova EI; Palchevska O; Lukash T; Dominguez F; Britt W; Frolov I J Virol; 2022 Aug; 96(15):e0075322. PubMed ID: 35876526 [TBL] [Abstract][Full Text] [Related]